Associated factors with antipsychotic use in assisted living facilities: A cross-sectional study of 4367 residents

Age and Ageing

Volumn 40, Issue 3, 2011, Pages 368-375

  Larrayadieu, Agnes ^a   van Kan, Gabor Abellan ^a   Piau, Antoine ^a   Martin, Maria Soto ^a   Nourhashemi, Fati ^a,b   Rolland, Yves ^a,b   Vellas, Bruno ^a,b  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Antipsychotics; Elderly; Nursing homes; Older adults

Indexed keywords

NEUROLEPTIC AGENT;

AGED; ARTICLE; ASSISTED LIVING FACILITY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; DEMENTIA; DRUG USE; FEMALE; FRANCE; HUMAN; MALE; MEDICAL RECORD; MENTAL DISEASE; NEUROPSYCHIATRIC SYMPTOMS; OFF LABEL DRUG USE; PRIORITY JOURNAL; RESIDENTIAL HOME; VIOLENCE; WANDERING BEHAVIOR;

AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; ASSISTED LIVING FACILITIES; CROSS-SECTIONAL STUDIES; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; FRANCE; HUMANS; LOGISTIC MODELS; MALE; MENTAL DISORDERS; PREVALENCE; QUESTIONNAIRES;

EID: 79955427442     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/afr032     Document Type: Article

References (29)

1. Oborne CA, Hooper R, Li KC et al. An indicator of appropriate neuroleptic prescribing in nursing homes. Age Aging 2002; 31: 435-9.
2. Briesacher BA, Limcangco R, Simoni-Wastila L et al. The quality of antipsychotic drug prescribing in nursing homes. Arch Intern Med 2005; 165: 1280-5.
3. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/01/WC500054057.pdf (accessed 5 May 2010).
4. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm (accessed 5 May 2010).
5. Ballard C, Waite J. The effectiveness of atypical antipsychotics fro the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006; CD003476.
6. Schneider LS, Tariot PN, Dagerman KS et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006; 355: 1525-38.
7. Wills P, Claesson CB, Fratiglioni L, Fastbom J, Thorslund M, Winblad B. Drug use by demented and non-demented elderly people. Age Ageing 1997; 26: 383-91.
8. Lee PE, Gill SS, Freedman M, Bronskill SE, Hillmer MP, Rochon PA. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 2004; 329: 75.
9. Ballard C, Lana MM, Theodoulou M et al. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Med 2008; 5: e76.
10. Rolland Y, Abellan van Kan G, Hermabessiere S, Gerard S, Gillette-Guyonnet S, Vellas B. Descriptive study of nursing home residents from the REHPA network. J Nutr Health Aging 2009; 13: 679-83.
11. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245-51.
12. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of ADL. A standardized measure of biological and psychological function. JAMA 1963; 185: 914-19.
13. Bewick V, Cheek L, Ball J. Statistics review 14: logistic regression. Critical Care 2005; 9: 112-8.
14. Liperoti R, Mor V, Lapane KL, Pedone C, Gambassi G, Bernabei R. The use of atypical antipsychotics in nursing homes. J Clin Psychiatry 2003; 64: 1106-12.
15. Alanen HM, Finne-Soveri H, Noro A, Leinonen E. Use of antipsychotics among nonagenarian residents in long-term institutional care in Finland. Age Aging 2006; 35: 508-13.
16. Seitz DP, Gruneir A, Conn DK et al. Cholinesterase inhibitor use in U.S. nursing homes: results from the national nursing home survey. J Am Geriatr Soc 2009; 57: 2269-74.
17. Voyer P, Verreault R, Nkogho Mengue PG et al. Determinants of neuroleptics drug use in long-term facilities for elderly persons. J Appl Gerontol 2005; 24: 179-95.
18. Kamble P, Chen H, Sherer J, Aparasu RR. Antipsychotic drug use among elderly nursing home residents in the United States. Am J Geriatr Pharmacother 2008; 6: 187-97.
19. Stella F, Caetano D, Pacheco JL, Sé EV, Lacerda AL. Factors influencing psychotropic prescription by non-psychiatrist physicians in a nursing home for the elderly in Brazil. Sao Paulo Med J 2006; 124: 253-6.
20. Jano E, Johnson M, Chen H, Aparasu RR. Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004. Curr Med Res Opin 2008; 24: 709-16.
21. Kamble P, Sherer J, Chen H, Aparasu RR. Off-label use of second-generation antipsychotic agents among elderly nursing home residents. Psychiatr Serv 2010; 61: 130-6.
22. Alexopoulos GS, Streim JE, Carpenter D et al. Expert consensus panel for using antipsychotic drugs in older patients. J Clin Psychiatry 2004; 65: 5-99.
23. Glick ID, Murray SR, Vasudevan P, Marder SR, Hu RJ. Treatment with atypical antipsychotics: new indications and new populations. J Psychiatr Res 2001; 35: 187-91.
24. Macdonald AJ, Carpenter GI, Box O et al. Dementia and use of psychotropic medication in non-'Elderly Mentally Infirm' nursing homes in South East England. Age Aging 2002; 31: 58-64.
25. Rossom RC, Rector TS, Lederle FA, Dysken MW. Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia?. J Am Geriatr Soc 2010; 58: 1027-34.
26. Ballard C, Corbett A. Management of neuropsychiatric symptoms in people with dementia. CNS Drugs 2010; 24: 729-39.
27. Balzman C, Jeste DV, Meyer RE et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry 2008; 69: 889-98.
28. Ballard CG, Gauthier S, Cummings JL et al. Management of agitation and aggression associated with Alzheimer's disease. Nat Rev Neurol 2009; 5: 245-55.
29. Chen Y, Briesacher BA, Field TS, Tjia J, Lau DT, Gurwitz JH. Unexplained variation across US Nursing Homes in antipsychotic prescribing rates. Arch Intern Med 2010; 170: 89-95.